Company Overview and News


Add ATRS
to your dashboard

Headline News

SHAREHOLDER ALERT: Pomerantz Law Reminds Shareholders with Losses on their Investment in Antares Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - ATRS

2017-11-18 accesswire
NEW YORK, NY / ACCESSWIRE / November 18, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-08945, is on behalf of a class consisting of investors who purchased or otherwise acquired Antares securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934. (49-0)

SHAREHOLDER ALERT: Pomerantz Law Reminds Shareholders with Losses on their Investment in Antares Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - ATRS

2017-11-17 accesswire
NEW YORK, NY / ACCESSWIRE / November 16, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-08945, is on behalf of a class consisting of investors who purchased or otherwise acquired Antares securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934. (49-0)

ANTARES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Antares Pharma, Inc. To Contact The Firm

2017-11-15 accesswire
NEW YORK, NY / ACCESSWIRE / November 15, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) of the December 22, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. (34-0)

IMPORTANT ANTARES PHARMA, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Investors Who Purchased Antares Pharma, Inc.

2017-11-15 accesswire
NEW YORK, NY / ACCESSWIRE / November 15, 2017 / Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Antares Pharma, Inc. (''Antares'' or the ''Company'') (NASDAQ: ATRS) in the United States District Court for the District of New Jersey on behalf of a class consisting of investors who purchased or otherwise acquired Antares securities on from December 21, 2016 through October 12, 2017, inclusive (the ''Class Period''). (49-0)

Analysts’ Recommendations for Antares Pharma in November 2017

2017-11-15 marketrealist
Antares Pharma (ATRS) operates in the injectable drug delivery market. According to a February 2017 report by MarketsandMarkets, the global injectable drug delivery market is expected to grow to $624.5 billion by 2021. This trend represents a CAGR1 of 11.5% from 2016 to 2021. (34-0)

Analysts’ Recommendations for Antares Pharma in November 2017

2017-11-15 marketrealist
Antares Pharma (ATRS) operates in the injectable drug delivery market. According to a February 2017 report by MarketsandMarkets, the global injectable drug delivery market is expected to grow to $624.5 billion by 2021. This trend represents a CAGR1 of 11.5% from 2016 to 2021. (34-0)

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline - December 22, 2017

2017-11-15 accesswire
NEW YORK, NY / ACCESSWIRE / November 15, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) securities and certain of its officers, on behalf of a class who purchased Antares shares between December 21, 2016, and October 12, 2017, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www. (49-0)

Antares Pharma On Sale

2017-11-14 seekingalpha
Antares stock had dropped 61% from a recent high after the company received notification from the FDA that it would not approve Xyosted in October. (186-3)

The Sum Of All Fears For This Small Pharma

2017-11-10 seekingalpha
A sum of the parts valuation shows decent value despite the amount of fear currently in the stock. (36-0)

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Antares Pharma, Inc. (ATRS) & Lead Plaintiff Deadline - December 22, 2017

2017-11-08 accesswire
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) securities and certain of its officers, on behalf of a class who purchased Antares shares between December 21, 2016, and October 12, 2017, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www. (49-0)

SHAREHOLDER ALERT: Pomerantz Law Reminds Shareholders with Losses on their Investment in Antares Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - ATRS

2017-11-07 accesswire
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-08945, is on behalf of a class consisting of investors who purchased or otherwise acquired Antares securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934. (49-0)

Antares Pharma's (ATRS) CEO Bob Apple on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Ladies and gentlemen, welcome to the Antares Pharma’s Third Quarter 2017 Operating and Financial Results Conference Call. Throughout today's recorded presentation all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. [Operator Instructions] (34-0)

Antares Pharma Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-07 seekingalpha
The following slide deck was published by Antares Pharma Inc. in conjunction with their 2017 Q3 earnings call. (34-0)

SHAREHOLDER ALERT: Pomerantz Law Reminds Shareholders with Losses on their Investment in Antares Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - ATRS

2017-11-04 accesswire
NEW YORK, NY / ACCESSWIRE / November 4, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-08945, is on behalf of a class consisting of investors who purchased or otherwise acquired Antares securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934. (49-0)

SHAREHOLDER ALERT: Pomerantz Law Reminds Shareholders with Losses on their Investment in Antares Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - ATRS

2017-11-01 accesswire
NEW YORK, NY / ACCESSWIRE / November 1, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-08945, is on behalf of a class consisting of investors who purchased or otherwise acquired Antares securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934. (49-0)

Stock Research Report

Antares Pharma, Inc. is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. Antares Pharma has a portfolio of proprietary and partnered pro...

Click for full article
CUSIP: 036642106